Skip to content
sellWeak cluster of 1210b5-1 plan

Patrick R. O'Neil sold $1.4M of IONS

EVP CLO & General Counsel at IONIS PHARMACEUTICALS INC. 21,000 shares at an average of $64.56, traded Sep 9, 2025, filed Sep 11, 2025.

Warning score
30
Value
$1.4M
21,000 shares
Holdings after
57,130
-27% from before
From 52-week low
+152%
low $25.51, close $64.40
From 52-week high
0%
high $64.40, as of Sep 9, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $1.4M at market
    +25
  • Share of holdings sold
    Sold 27% of holdings
    +10
  • Cluster
    12 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

IONSOct 9, 2026 · close 45.28
Since filing Sep 11, 2025: -29.3%SPY +20.0% · excess -49.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000874015-25-000231, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Sep 9, 2025MOption exercise
Common Stock10b5-1
+20,000$60.89$1.2M77,130Sep 11, 2025
Sep 9, 2025SOpen-market sale
Common Stock10b5-1
-20,000$64.56$1.3M57,130Sep 11, 2025
Sep 9, 2025MOption exercise
Common Stock10b5-1
+1,000$56.78$57k58,130Sep 11, 2025
Sep 9, 2025SOpen-market sale
Common Stock10b5-1
-1,000$64.56$65k57,130Sep 11, 2025
Sep 9, 2025MOption exercise
Non-Qualified Stock Option (right to buy)derivative10b5-1
-1,000$0.00$057,203Sep 11, 2025
Sep 9, 2025MOption exercise
Non-Qualified Stock Option (right to buy)derivative10b5-1
-20,000$0.00$034,461Sep 11, 2025

Related signals

Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
25Weak
IONSsell 210b5-1
IONIS PHARMACEUTICALS INC
Joseph Baroldi
EVP, Chief Business Officer
$452k
5,635 shares
-55%
7Weak
IONSsell 210b5-1
IONIS PHARMACEUTICALS INC
Spencer R Berthelsen
director
$588k
8,000 shares
-5%
0Weak
IONSsell10b5-1
IONIS PHARMACEUTICALS INC
Spencer R Berthelsen
director
$605k
8,000 shares
-5%
13Weak
IONSsell 210b5-1
IONIS PHARMACEUTICALS INC
Joseph Baroldi
EVP, Chief Business Officer
$117k
1,626 shares
-3%
29Weak
IONSsell 2
IONIS PHARMACEUTICALS INC
Joseph Baroldi
EVP, Chief Business Officer
$419k
5,619 shares
-11%
16Weak
IONSsell 2
IONIS PHARMACEUTICALS INC
Brian Birchler
EVP, Corp and Development Ops
$73k
973 shares
-1%
26Weak
IONSsell 510b5-1
IONIS PHARMACEUTICALS INC
Eugene Schneider
EVP, Chf Clinical Develop Ofcr
$412k
5,812 shares
-8%
47Moderate
IONSsell 1110b5-1
IONIS PHARMACEUTICALS INC
Elizabeth L Hougen
EVP, Finance & CFO
$16M
225,220 shares
-73%
40Moderate
IONSsell 1110b5-1
IONIS PHARMACEUTICALS INC
Kyle Jenne
EVP, Chf GL Pdt Str Ofcr
$2.8M
37,277 shares
-76%
40Moderate
IONSsell 1110b5-1
IONIS PHARMACEUTICALS INC
Brett P Monia
Chief Executive Officer
$12M
160,773 shares
-44%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Patrick R. O'Neil sold $1.4M of IONS | InsiderTell